IHT Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

IHT Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-23	Closed	-$2K	–	448
2018 Q1	$2K	Sell	23 -9	-28%	-$1.16K	﹤0.01%	1479
2017 Q4	$4K	Sell	32 -230	-88%	-$28.9K	﹤0.01%	1366
2017 Q3	$32K	Buy	262 +64	+32%	+$5.46K	0.01%	636
2017 Q2	$16K	Hold	198	–	–	0.01%	833
2017 Q1	$9K	Hold	198	–	–	0.01%	863
2016 Q4	$8K	Buy	+198	New	+$8.29K	0.01%	829

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

IHT Wealth Management's ALNY Position: Q2 2018 in Review

IHT Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2018, closing a stake of 23 shares — an estimated $2K sold.

IHT Wealth Management first reported a position in ALNY in Q4 2016 and held it in 6 quarters. The position peaked at $32K in Q3 2017. 310 funds tracked by Wall St. Rank hold ALNY as of Q2 2018.

IHT Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
IHT Wealth Management sold 23 Alnylam Pharmaceuticals shares in Q2 2018, an estimated $2K.
IHT Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and held it in 6 quarters.
IHT Wealth Management's Alnylam Pharmaceuticals position peaked at $32K in Q3 2017.
310 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.